Abstract Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …

Lung cancer remains the leading cause of cancer deaths in the United States. In the past
decade, significant advances have been made in the science of non–small cell lung cancer …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

Importance Administration of anti–programmed cell death protein 1 (anti–PD-1) is now
standard therapy in advanced non–small cell lung cancer (NSCLC). However, immune …

Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the
regulatory interactions that limit T cell cytotoxicity to tumours. Current agents target either …

Paraneoplastic neurological syndromes (PNSs) comprise a group of disorders that can
affect any part of the nervous system in patients with cancer and frequently result from …

Oncology has recently undergone a revolutionary change with widespread adoption of
immunotherapy for many cancers. Immunotherapy using monoclonal antibodies against …

Objective Immune checkpoint inhibitors (ICI s) for cancer therapy frequently induce immune‐
related adverse effects (IRAE s). Therefore, most patients with preexisting autoimmune …

Immune checkpoints arise from physiological changes during tumorigenesis that
reprogramme inflammatory, immunological and metabolic processes in malignant lesions …

The approval of immunotherapeutic agents and immunotherapy-based combination
strategies in recent years has revolutionized the treatment of patients with advanced renal …